Skip to content

Study · Animal study (in vivo) · mouse · 1993

6 results

Thymosin beta 4 synergizes with human granulocyte-macrophage colony-stimulating factor in maintaining bone marrow proliferation.

Moscinski LC, Naylor PH, Oliver J, Goldstein AL

Immunopharmacology1 Jul 1993Cited by 9 (Europe PMC)

PMID8407287 (opens in a new tab)DOI10.1016/0162-3109(93)90068-2 (opens in a new tab)PepBankPUB-08407287
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, whole synthetic thymosin beta‑4 protected against ara-C toxicity more effectively than the N-terminal tetrapeptide.

    In plain wordsIn mice, whole thymosin beta‑4 protected against the toxicity of ara-C better than its N-terminal tetrapeptide.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseProtection from ara-C toxicity
    Study

    mousen: not reported in source

    Mice given LD50 doses of ara-C
    Comparator
    N-terminal tetrapeptide of thymosin beta 4
    Outcome group
    Mortality · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the present study, we have extended these observations by demonstrating that whole synthetic T beta 4 is more effective than the N-terminal tetrapeptide in protecting mice from the toxicity of ara-C.
  2. 02LabIn vitro (cells)Efficacy outcome

    In short-term liquid cultures of enriched human bone marrow, thymosin beta‑4 failed to inhibit cell proliferation.

    In plain wordsIn human bone marrow cells in lab cultures, thymosin beta‑4 did not stop cell growth.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeBone marrow cell proliferation
    Study

    humann: not reported in source

    Enriched human bone marrow liquid cultures
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In short-term liquid cultures studied sequentially over 1-7 days, T beta 4 failed to inhibit cell proliferation
    1 context sentence
    Summary · context
    To determine if inhibition of cell cycle progression also occurs in committed human bone marrow progenitors treated with T beta 4, we have investigated the effects of synthetic T beta 4 on proliferating and unstimulated enriched human bone marrow.
  3. 03LabIn vitro (cells)Efficacy outcome

    In human bone marrow cultures, thymosin beta‑4 maintained the proliferative effect of GM-CSF on days 5-7 after maximum stimulation.

    In plain wordsIn human bone marrow cells in lab cultures, thymosin beta‑4 helped keep up the growth effect of GM-CSF on later days.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseGM-CSF proliferative effect on days 5-7
    Study

    humann: not reported in source

    Enriched human bone marrow liquid cultures
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but maintained the proliferative effect of granulocyte-macrophage colony stimulating factor (GM-CSF) on days following maximum stimulation (days 5-7).
    1 context sentence
    Summary · context
    To determine if inhibition of cell cycle progression also occurs in committed human bone marrow progenitors treated with T beta 4, we have investigated the effects of synthetic T beta 4 on proliferating and unstimulated enriched human bone marrow.
  4. 04LabIn vitro (cells)Efficacy outcome

    In human bone marrow cultures, thymosin beta‑4 had no effect before the fifth day in culture.

    In plain wordsIn human bone marrow cells in lab cultures, thymosin beta‑4 had no effect before day 5.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeEffect before day 5 in culture
    Study

    humann: not reported in source

    Enriched human bone marrow liquid cultures
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No effect was noted before the fifth day in culture
    1 context sentence
    Summary · context
    To determine if inhibition of cell cycle progression also occurs in committed human bone marrow progenitors treated with T beta 4, we have investigated the effects of synthetic T beta 4 on proliferating and unstimulated enriched human bone marrow.
  5. 05LabIn vitro (cells)Efficacy outcome

    In human bone marrow cultures, thymosin beta‑4 had no demonstrable effect in the absence of added GM-CSF.

    In plain wordsIn human bone marrow cells in lab cultures, thymosin beta‑4 had no effect without added GM-CSF.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeEffect without added GM-CSF
    Study

    humann: not reported in source

    Enriched human bone marrow liquid cultures
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    nor did T beta 4 exert any demonstrable effect in the absence of added GM-CSF.
    1 context sentence
    Summary · context
    To determine if inhibition of cell cycle progression also occurs in committed human bone marrow progenitors treated with T beta 4, we have investigated the effects of synthetic T beta 4 on proliferating and unstimulated enriched human bone marrow.
  6. 06LabIn vitro (cells)Mechanism

    In human bone marrow cultures stimulated with GM-CSF, any effect of thymosin beta‑4 required its presence on or before day 3 of GM-CSF stimulation.

    In plain wordsIn human bone marrow cells in lab cultures, thymosin beta‑4 had an effect only if present by day 3 of GM-CSF stimulation.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableTiming of thymosin beta 4 exposure needed for effect
    Study

    humann: not reported in source

    Enriched human bone marrow liquid cultures
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Any observable effect of T beta 4 required that it be present in the cultures on or before day 3 of GM-CSF stimulation.
    1 context sentence
    Summary · context
    To determine if inhibition of cell cycle progression also occurs in committed human bone marrow progenitors treated with T beta 4, we have investigated the effects of synthetic T beta 4 on proliferating and unstimulated enriched human bone marrow.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.